BRIEF—J&J wins Invokana approval for CV events in diabetes

Johnson & Johnson has announced that the US Food and Drug Administration has approved Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular (CV) events due to a cardiovascular cause in certain people with type 2 diabetes.

Global therapy area head James List said: “This FDA approval makes Invokana the only oral type 2 diabetes treatment indicated to reduce the risk of heart attack, stroke or CV death. It is an important step forward for patients and the physicians who treat them.”

“Not only does Invokana enable patients to control their diabetes symptoms by lowering their A1C levels, but it now also helps protect them from potentially devastating cardiovascular events.”